# Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

> **NCT04297995** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 131 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** HLX10
- **DRUG:** HLX07
- **DRUG:** HLX07 placebo
- **DRUG:** Cisplatin/Carboplatin
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT04297995
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-29
- **Primary completion:** 2024-05-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 131 (ESTIMATED)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04297995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04297995, "Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04297995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*